Table 1 Clinico-pathological characteristics of the patient cohort in relation with PD-L1 expression (clone E1L3N)

From: Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases

Factors

Number of patients

PD-L1 expression

P-value

 

Total cohort

PD-L1 evaluation

<1%

1–<50%

≥50%

 

Total

378

372

163 (44%)

135 (36%)

74 (20%)

 

Gender

 Male

320 (85%)

315

144 (46%)

111(35%)

60 (19%)

0.217

 Female

58 (15%)

57

19 (33%)

24 (42%)

14 (25%)

 

Age, median (min–max)

69 (36.5–85.1)

 

69.5 (43.2–85.1)

67.8 (43.8–83.9)

70.9 (36.5–84.9)

0.825

pT stage

 T1a

38

36

12 (33%)

19 (53%)

5 (14%)

0.110

 T1b

53

53

29 (55%)

15 (28%)

9 (17%)

 

 T2a

123

120

53 (44%)

49 (41%)

18 (15%)

 

 T2b

56

56

23 (41%)

16 (29%)

17 (30%)

 

 T3

79

78

31 (40%)

29 (37%)

18 (23%)

 

 T4

29

29

15 (52%)

7 (24%)

7 (24%)

 

pN stage

 N0

220

216

94 (44%)

81 (37%)

41 (19%)

0.571

 N1

116

115

55 (48%)

38 (33%)

22 (19%)

 

 N2

42

41

14 (34%)

16 (39%)

11 (27%)

 

M

 M0

371

365

160 (44%)

132 (36%)

73 (20.0%)

0.905

 M1

7

7

3 (43%)

3 (43%)

1 (14%)

 

Stage

 IA

69 (18%)

68

31 (46%)

26 (38%)

11 (16%)

0.703

 IB

80 (21%)

77

32 (42%)

31 (40%)

14 (18%)

 

 IIA

77 (20%)

77

38 (49%)

29 (38%)

10 (13%)

 

 IIB

51 (14%)

51

21 (41%)

17 (33%)

13 (26%)

 

 IIIA

87 (23%)

85

34 (40%)

27 (32%)

24 (28%)

 

 IIIB

7 (2%)

7

4 (57%)

2 (29%)

1 (14%)

 

 IV

7 (2%)

7

3 (43%)

3 (43%)

1 (14%)

 

Grade

 G1

 

10

8 (80%)

2 (20%)

0

0.073

 G2

 

140

58 (41%)

58 (41%)

24 (17%)

 

 G3

 

176

73 (42%)

62 (35%)

41 (23%)

 

Resection

 R0

330

326

144 (44%)

117 (36%)

65 (20%)

0.966

 R1

45

43

18 (42%)

17 (39%)

8 (19%)

 

 R2

3

3

1 (33%)

1 (33%)

1 (33%)

 

Smoking

 Pack-years, median (min–max)

50 (2–200)

 

50.0 (5.0–150.0)

45.0 (2.0–200.0)

50.0 (16.0–150.0)

0.425

Back to article page